Barrett’s esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a cancer associated with a dismal 5-year survival rate (Am J Gastroenterol 2017;112(7):1032-1048). Despite all the advances in this field, we have had minimal impact on the incidence, morbidity and mortality related to this lethal cancer. This has provided the impetus for major gastroenterology societies to propose quality indicators to guide diagnostic, surveillance and treatment strategies including endoscopic eradication therapies and ultimately improve outcomes associated with EAC (Gastroenterology 2015;149(6):1599-1606, Am J Gastroenterol 2017;112(7)1032-1048). Adenoma detection rate (ADR) is a well-established quality indicator in colon cancer screening; a measure that not only has face validity but also associated with risk of interval colorectal cancer. Whether a similar quality indicator can be utilized in patients with BE undergoing their index screening endoscopy is the focus of this summary.

巴雷特食管（BE）是食管腺癌（EAC）的唯一已知前体，食管腺癌是一种与令人沮丧的5年生存率相关的癌症（Am J Gastroenterol 2017; 112（7）：1032-1048）。尽管在该领域取得了所有进展，但我们对与该致死性癌症相关的发病率，发病率和死亡率的影响却很小。这为主要胃肠病学学会提供了动力，以提出质量指标来指导诊断，监测和治疗策略，包括内镜根除疗法并最终改善与EAC相关的结局（《胃肠病学》 2015; 149（6）：1599-1606，Am J Gastroenterol 2017; 112（7）1032-1048）。腺瘤检出率（ADR）是结肠癌筛查中公认的质量指标；一种不仅具有面部有效性，而且与间隔性大肠癌风险相关的措施。